What's the main difference between semaglutide and tirzepatide? Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist with 15-20% average weight loss. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist with 20-25% average weight loss. Both are FDA-approved, administered weekly, and cost $900-$1,350/month without insurance. Tirzepatide shows superior weight loss but both have similar side effect profiles.
"Semaglutide vs tirzepatide" remains one of the highest-intent GLP searches because it combines two priorities: outcomes and affordability.
Quick Comparison Table
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Administration | Weekly injection, daily oral (Rybelsus) | Weekly injection |
| Average weight loss | 15-20% of body weight | 20-25% of body weight |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation |
| Cost (without insurance) | ~$900-1,350/month | ~$900-1,350/month |
| FDA-approved for | Type 2 diabetes, weight loss | Type 2 diabetes, weight loss |
Key Points
- Mechanism differs: Semaglutide targets one hormone pathway (GLP-1), while tirzepatide targets two (GIP and GLP-1)
- Weight loss advantage: Tirzepatide shows 5-7% greater average weight loss in head-to-head trials
- Similar side effects: Both cause nausea, decreased appetite, and digestive issues
- Same dosing schedule: Both are typically taken once weekly (except oral semaglutide)
- Cost is comparable: Both have similar list prices and manufacturer savings programs
Mechanism in Plain Language
- Semaglutide: GLP-1 receptor agonist.
- Tirzepatide: dual GIP/GLP-1 receptor agonist.
For patients, this usually translates into a discussion about expected weight-loss response, tolerability, and dose escalation strategy.
Side Effects: Overlap and Differences
Both can cause:
- nausea
- decreased appetite
- constipation or diarrhea
- reflux/fullness
The intensity and timing vary person to person. Most side-effect decisions are made during dose increases, not day one.
Cost and Access Often Decide the Winner
Even when a patient prefers one option clinically, formulary rules can drive the final decision. That is why many people search both clinical comparisons and savings-card terms in the same session.
If you are trying to figure out what you will actually pay, see our guide to GLP-1 cost without insurance. For help lowering your monthly bill, check the Mounjaro savings card and Zepbound savings card guides.
Best Decision Framework
- Define your primary goal (weight, glycemic, or both).
- Compare expected side-effect tolerance.
- Confirm real out-of-pocket cost at your pharmacy.
- Build a follow-up schedule before first dose.
Bottom Line
The better medication is the one you can tolerate, afford, and stay on with proper follow-up.
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary.